Table 3.

Patient characteristics of PD-L1⁺ and PD-L1^– DLBCL

Characteristic	PD-L1+ (n = 34)		PD-L1– (n = 239)				P*	P†
	No.	%	mPD-L1+ (n = 53)		mPD-L1– (n = 186)
			No.	%	No.	%
Sex (male/female)	23/11	68/32	24/29	45/55	95/91	51/49	.07	.42
Age (y)
Median	74.5		73		70
Range	30-92		29-87		21-93
>60	26	76	43	81	132	71	.78	.14
ECOG PS >1	13	38	15	28	56	30	.32	.80
Extranodal sites >1	14	41	15	28	49	26	.09	.78
B symptoms	16	47	17	32	37	20	.004	.06
Elevated serum LDH	26	76	35	66	114	61	.10	.53
Elevated serum sIL-2R	33 of 33	100	41 of 50	82	141 of 181	82	.0005	.97
Ann Arbor stage >2	24	71	35	66	101	54	.12	.13
IPI risk group
Low (0–2)	10	29	16	30	98	53	.04	.005
High (3–5)	24	71	37	70	88	47
DLBCL subtypes
GCB	7	21	14	26	90	48	.008	.004
non-GCB	27	79	39	74	96	52
EBV-ISH positive	2	6	11	21	11	6	.75‡	.002‡
Treatment
R-CHOP/R-CHOP-like	26	76	41	77	151	81
First-line ASCT	2	6	4	8	4	2
Other chemotherapy	5	15	6	11	21	11
Radiotherapy (total)	5	15	12	23	41	22
Radiotherapy only	1	3	2	4	8	4
No therapy	0	0	0	0	2	1
	(n = 33)		(n = 51)		(n = 176)
Treatment response
CR/CRu	21	64	41	80	127	72	.21	.28
PR	8	24	7	14	23	13
SD or PD	3	9	3	6	24	14
Not evaluable	1	3	0	0	2	1

ASCT, autologous stem cell transplantation; CR, complete response/remission; CRu, uncertain complete response/remission; IPI, international prognostic index; PD, progressive disease; PR, partial response/remission; SD, stable disease.

^*PD-L1⁺ vs PD-L1^–.

^†mPD-L1⁺ vs mPD-L1^–.

^‡Fisher’s exact test.